SCHEMBL3015358

SCHEMBL3015358

COc1ccc(S(=O)(=O)C2CCN(c3nc(-c4cc(F)cc(F)c4)cs3)CC2)cc1OC

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 12/20 0.50
RAB9A P51151 9/20 0.50
NPC1 O15118 7/20 0.50
MAPT P10636 5/20 0.50
RECQL P46063 2/20 0.48
USP2 O75604 1/20 0.48
HSD17B10 Q99714 1/20 0.48
L3MBTL1 Q9Y468 3/20 0.47
AR P10275 1/20 0.46
ALDH1A1 P00352 2/20 0.45
TDP1 Q9NUW8 2/20 0.44
KDM4E B2RXH2 1/20 0.44
NTSR1 P30989 1/20 0.44
MAPK1 P28482 2/20 0.44
GAA P10253 1/20 0.44
LMNA P02545 1/20 0.42
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2999521 0.94 SMN1; SMN2 (0.46) SMN1; SMN2RAB9ANPC1MAPTRECQL
SCHEMBL3014772 0.90 SMN1; SMN2 (0.62) SMN1; SMN2RAB9ANPC1MAPTRECQL
SCHEMBL3003895 0.90 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1MAPTRECQL
SCHEMBL3019269 0.90 RAB9A (0.52) SMN1; SMN2RAB9ANPC1MAPTRECQL
SCHEMBL3012500 0.90 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1MAPTRECQL
SCHEMBL2999759 0.90 MAPK1 (0.57) SMN1; SMN2RAB9ANPC1MAPTRECQL
SCHEMBL3023403 0.89 SMN1; SMN2 (0.53) SMN1; SMN2RAB9ANPC1MAPTRECQL
SCHEMBL3011405 0.89 SMN1; SMN2 (0.58) SMN1; SMN2RAB9ANPC1MAPTRECQL
SCHEMBL3011075 0.89 MAPT (0.54) SMN1; SMN2RAB9ANPC1MAPTRECQL
SCHEMBL15671707 0.89 RAB9A (0.52) SMN1; SMN2RAB9ANPC1MAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.